



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학석사 학위논문

Endogenous prostaglandin E_2
potentiates anti-inflammatory
phenotype of macrophage
through the CREB-C/EBP β
cascade

내인성 PGE_2 의 CREB-C/EBP β
cascade 를 통한 항염증성
큰포식세포 유도 기전 연구

2015 년 2 월

서울대학교 대학원
의학과 미생물학 전공
정 다 운

내인성 PGE₂의 CREB-C/EBP β
cascade 를 통한 항염증성
큰포식세포 유도 기전 연구

Endogenous prostaglandin E₂
potentiates anti-inflammatory
phenotype of macrophage
through the CREB-C/EBP β
cascade

February, 2015

The Department of Microbiology and
Immunology in Seoul National University
College of Medicine Graduate School

Daun Jung

Endogenous prostaglandin E₂
potentiates anti-inflammatory
phenotype of macrophage
through the CREB-C/EBP β
cascade

by
Daun Jung
(Supervised Prof. Seung Hyeok Seok)

A thesis submitted to the Department of Medicine
in partial fulfillment of the requirements for the
Degree of Master of Science in Medicine
(Microbiology and Immunology)
at Seoul National University College of Medicine

January, 2015

Approved by Thesis Committee:

Professor _____ Chairman
Professor _____ Vice chairman
Professor _____

내인성 PGE₂의 CREB-C/EPB β
cascade 를 통한 항염증성
큰포식세포 유도 기전 연구

지도교수 석 승 혁

이 논문을 의학석사 학위논문으로 제출함

2014 년 10 월

서울대학교 대학원
의학과 미생물학 전공
정 다 운

정다운의 의학석사 학위논문을 인준함

2015 년 1 월

위 원 장 _____ (인)

부위원장 _____ (인)

위 원 _____ (인)

ABSTRACT

Macrophages have important functions in tissue homeostasis, but the exact mechanisms regarding wide spectrum of macrophage phenotype remain unresolved. In this study, we report that naïve macrophages produce prostaglandin E₂ (PGE₂) endogenously, resulting in anti-inflammatory gene expression upon differentiation induced by macrophage colony stimulating factor (M-CSF). Cyclooxygenase (COX) inhibition by indomethacin reduced endogenous PGE₂ production of macrophages and subsequently reduced arg1, IL10 and Mrc1 gene expressions. Of note, PGE₂ phosphorylates CREB via EP2 and EP4 receptor ligation, thereby transcriptionally increasing C/EBPβ expression in Balb/c bone marrow derived macrophages (BMDM). Activated CREB directly binds to the CREB-responsive element of the C/EBPβ promoter, such that PGE₂ ultimately reinforces arg1, IL10 and Mrc1 gene expression. Cyclic AMP activator forskolin also phosphorylated CREB and induced the C/EBPβ cascade, but this was completely blocked by the PKA inhibitor, H89. Consequently, M-CSF grown macrophages inhibited T cell proliferation but the inhibition ability was reduced when the COX is inhibited by indomethacin or macrophage C/EBPβ expression was decreased by siRNA transduction. Our results collectively describe the molecular basis for homeostatic macrophage differentiation by endogenous PGE₂.

Keywords: Prostaglandin E₂ , macrophage, CREB, C/EBPβ

Student number: 2013 – 21741

CONTENTS

Abstract.....	i
Contents	ii
List of tables and figures.....	iii
List of abbreviations	v
Introduction	1
Material and Methods	4
Results	9
Discussion	25
References	29
Abstract in Korean	34

LIST OF TABLES AND FIGURES

Table 1. Primer sequences used in this study	14
Figure 1. Endogenous PGE ₂ production is required for Arg1, IL10 and Mrc1 macrophage gene expression	15
Figure 2. PGE ₂ phosphorylates CREB and increases C/EBPβ expression.	16
Figure 3. PGE ₂ activates CREB through EP4 and EP2 receptors	17
Figure 4. PGE ₂ activates CREB through the cAMP/PKA signaling pathway.....	18
Figure 5. PGE ₂ induces Arg1, IL10 and Mrc1 macrophage gene expression through C/EBPβ.	19
Figure 6. Endogenous cyclooxygenase and C/EBPβ in macrophages suppress T-cell proliferation.	20
Figure 7. Schematic representation of proposed mechanism by which endogenous PGE ₂ promotes anti-inflammatory macrophage differentiation through the CREB/CEBPβ cascade.....	21
Supplementary Figure 1. F4/80 ⁺ cell populations of differentiating bone marrow derived macrophages.....	22
Supplementary Figure 2. EP receptor expression on bone marrow derived macrophages from C57BL/6J.....	23
Supplementary Figure 3. EP receptor expression on peritoneal	

macrophages of Balb/c and C57BL/6J mice.24

LIST OF ABBREVIATIONS

PGE₂: Prostaglandin E₂

CREB: cAMP response element-binding protein

C/EBP β : CCAAT-enhancer-binding proteins beta

INTRODUCTION

Macrophages play a pivotal role in the innate immune system by sensing and killing microbes. Moreover, macrophages have important roles in almost every aspect of an organism's biology including development, tissue repair, and homeostasis (1). Tissue macrophages are highly heterogenous in terms of their functions and phenotypes as a consequence of adapting to different tissue environments, where they monitor the local environment and maintain homeostasis (2).

Historically, all tissue macrophages were considered to be derived from circulating monocytes that originate from hematopoietic stem cells (3). Recent studies revealed that a substantial portion of tissue macrophages arise from the yolk sac during embryogenesis, and are maintained by local proliferation (4). Regardless of their origin, macrophages acquire unique characteristics depending on their tissue specific microenvironment (5). Macrophage colony-stimulating factor (M-CSF) generally differentiates macrophages with homeostatic function *in vivo* (6). Likewise, tissue specific factors such as GM-CSF in lung alveoli and fat cell derived adipokines in adipose tissue also affect macrophage phenotypes. Infections greatly change local tissue microenvironments, particularly when blood derived monocytes infiltrate infected areas and differentiate into macrophages. Parasite induced IL-4 or IL-13 drive macrophages into alternatively activated M2 phenotypes, but most other microbes induce Th1 immune responses and drive macrophages into classically activated phenotypes, which contribute to many pathological processes (7). Accordingly, there is much interest in studying the exact factors that dictate macrophage phenotype changes for therapeutic applications.

Prostaglandin E₂ (PGE₂) is a lipid mediator derived from the metabolism of arachidonic acid by cyclooxygenase (COX). It is the most abundant prostanoid in most tissues, and it is a well-known regulator of numerous physiologic and pathophysiologic processes, including blood flow (8), parturition (9), fever and inflammation (10). While generally recognized as a mediator of active inflammation, promoting local vasodilation and local

attraction and activation of neutrophils, mast cells, and macrophages early during inflammation (11), it also promotes the induction of suppressive cytokine IL-10 and directly suppresses the production of multiple proinflammatory cytokines. This works to limit nonspecific inflammation as part of immune suppression associated with chronic inflammation (12). Importantly, its effects on macrophage function have been amply documented to be mainly suppressive (11), as evidence by the increase in the levels of the intracellular second messenger cAMP generated upon ligation of EP2 and EP4 receptors (13). Notably, M-CSF induces functional COX-1 in developing macrophages (14), but whether endogenous PGE₂ is generated during macrophage differentiation and how PGE₂ affects the signals that regulate specialized macrophage characteristics remain poorly defined.

Specifically, PGE₂ signals via four known receptors (EP1-EP4), which primarily use the cAMP/PKA/CREB signaling pathway for the suppressive and regulatory functions of PGE₂ (11). Once serine 133 of CREB is phosphorylated, CREB interacts with its coactivator protein, CREB-binding protein (CBP), or p300, to initiate transcription of CREB-responsive genes (15). Meanwhile, a recent study showed that the transcription factor C/EBP β expression is induced by LPS mediated CREB activation and specifically regulates M2 macrophage-associated genes including arg1, IL10 and Mrc1 (16). Using a muscle injury model, CREB-mediated C/EBP β expression was determined to be required for upregulating M2-specific genes in infiltrating macrophages and muscle regeneration. Though PGE₂ more potently activates CREB than LPS, the PGE₂/CREB-C/EBP β axis and its effects on macrophage phenotype have not yet been examined.

We report here that M-CSF grown murine macrophages endogenously produce PGE₂ during differentiation. COX inhibition by indomethacin reduced endogenous PGE₂ production and subsequently reduced arg1, IL10 and Mrc1 gene expressions. PGE₂ phosphorylates CREB via EP2 and EP4 receptor ligation leading to cAMP/PKA activation. Phosphorylated CREB transcriptionally induces C/EBP β and consequent arg1, IL10 and Mrc1 gene expressions. Lastly, M-CSF grown macrophages inhibit T cell proliferation

and this was reduced when COX activity was inhibited or when endogenous C/EBP β was downregulated in differentiating macrophages. These results establish PGE₂ as the molecular basis of homeostatic macrophage differentiation with anti-inflammatory phenotype.

MATERIALS AND METHODS

Reagents

AH-23848, AH-6809, butaprost, CAY10598, forskolin, H89, PGE₂, SC-51089 and sulprostone were all purchased from Cayman Chemicals (Ann Arbor, MI). L-798,106 was obtained from Santa Cruz biotechnology (Dallas, Texas). Indomethacin was obtained from Sigma Aldrich (St. Louis, MO). All chemicals were dissolved in DMSO or ethanol and treated at the indicated concentration in Figure legends.

Cell line and cell culture

J774A.1 and RAW264.7 macrophage cell lines were generously provided by Dr. Cho NH (Seoul National University, Seoul, Korea). All cell lines were cultured at 37°C in a humidified incubator containing 5% CO₂ in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco Life Technologies, Grand Island, NY) and 1% penicillin–streptomycin (Gibco).

Preparation of bone marrow-derived macrophages

Murine bone-marrow-derived macrophages (BMDM) were derived from 6~9-week-old female BALB/c mice. Isolated bone marrow cells were cultured for 3 days at a density of 10⁶/ml in RPMI medium (Thermo, Waltham, Massachusetts) supplemented with 10% FBS (Gibco, Carlsbad, California), 10 units/ml penicillin, 10 µg/ml streptomycin, 2 mM L-glutamine (Gibco) and 20% L-cell conditioned medium (hereafter termed complete medium) at 37°C in a humidified atmosphere with 5% CO₂. All animal procedures were performed according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the Institution of Animal Care and Use Committee of Seoul National University, Korea. The protocol was approved by the Seoul National University Institute Animal Care and Use Committee (Approval Number SNU-120904-8-1).

Western blotting

Cells were lysed in RIPA buffer with protease inhibitor and phosphatase inhibitor (GenDepot, Houston, TX). Protein samples were separated on a 12% SDS-PAGE. After electrophoresis, proteins were transferred to nitrocellulose membrane (Millipore, Bedford, MA) and then washed with PBS containing 0.05% Tween 20 (PBST) and then blocked with PBS containing 5% nonfat dry milk for 1 h at room temperature. Membranes were then probed with primary antibodies including phospho-Ser133 CREB (#9191, Cell Signaling Technology, Danvers, MA), total CREB (#9197, Cell Signaling Technology), CEBP β (#3087, Cell Signaling Technology) and actin (sc-47778, Santa Cruz biotechnology) at 1/2000 overnight. After washing three times, blots were incubated with HRP-conjugated appropriate secondary antibodies (Santa Cruz Biotechnology) at 1/5000 for 1 h at room temperature. Immunoreactivity was detected using the PICO Lucent detection kit (G Biosciences, St. Louis, MO).

RNA isolation and Quantitative real-time PCR

RNA was solubilized in TRIzol reagent (Invitrogen) and extracted according to the manufacturer's instructions. cDNA was synthesized from 1 μ g total RNA and the levels of mRNA were determined by quantitative real-time PCR using the Taqman Universal Master Mix II (Applied Biosystems) or SYBR Green PCR Master Mix (Applied Biosystems) on a Prism 7900HT. The relative amount of each mRNA was normalized by GAPDH expression. The primer and probe sequences are listed in Table 1. Murine GAPDH primers and probe sets (VIC) were obtained from Applied Biosystems.

ELISA

PGE₂ levels in BM-derived macrophage culture supernatants were measured by ELISA kit according to the manufacturer's instruction (Cayman Chemical).

Small interfering RNA transfection

Small interfering RNA (siRNA) for C/EBP β and scramble control were obtained from Santa Cruz Biotechnology and transfected using Lipofectamine

RNAiMAX (Invitrogen) following the manufacturer's instructions. After 24h of J774 cell seeding, cells were treated with PGE₂ (10μM) for the times indicated in figure legends. RNAs were harvested for RT-PCR to analyze downregulation of C/EBPβ expression.

Transient transfection

Raw 264.7 macrophage cells were plated in 12-well plates at a density of 2 x10⁵/well. When the cells reached 60–70% confluence, cells were transiently transfected with wild-type CREB (pCMV-CREB Vector, Clontech), mutant CREB (pCMV-CREB133, Clontech), or a dominant-negative CREB (pCMV-KCREB, Clontech) vector using TransIT-LT1 Transfection reagent (Mirus Bio LLC, Madison) according to the manufacturer's instructions. After 24 h of transfection, cells were treated with PGE₂ (10μM) for another 4h.

Chromatin Immunoprecipitation(chIP)

Raw 264.7 cells were cross-linked with 1% formaldehyde in culture media for 10 min. Cross-linking was quenched by adding 0.125 M glycine to the medium and 10 min incubation. Cells were then washed, scraped in cold PBS, pelleted, and resuspended in ChIP lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) in a volume of 200 μl/million cells. Cell lysates were incubated on ice for 10 min. Chromatin was sheared by sonication for 10 s using water-sonication. After sonication, cellular debris was eliminated, and 200 μl lysate was diluted 10 times in ChIP dilution buffer (16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100, and 0.01% SDS) and cleared by incubation with 30 μl protein A agarose beads (Santa Cruz Biotechnology) for 1 h at 4 °C with rotation. Four micrograms of anti-CREB antibody (Cell Signaling) or non-immune rabbit IgG (Santa Cruz Biotechnology) were added and lysates were incubated 16 h at 4 °C on rotation. Protein A bead solution was added and the lysates were incubated 4 h at 4 °C on a rotating wheel. Beads were collected by centrifugation and washed in ChIP dilution buffer, ChIP dilution buffer with 500 mM NaCl, and twice in TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Finally, the beads were

resuspended in 100 µl TE and decrosslinked at 65 °C in the presence of 1 ng RNase for 4 h. Fifty nanograms of Proteinase K (Roche) and SDS to 0.5% were added and the samples were incubated 1 h at 42 °C. DNA was collected using QIAquick gel extraction kit (Qiagen) according to the manufacturer's instructions. Precipitated DNA was analyzed by PCR using the following conditions: 94 °C for 2 min, 30 times of (94 °C for 1 min, 58 °C for 1 min, 72 °C for 1 min), 72 °C for 5 min. The reactions were carried out with Promega Taq Polymerase as described by the manufacturer, using 2 µl DNA template and adding 5% DMSO. The PCR products were analyzed by electrophoresis on a 2% agarose gel.

Flow Cytometry

To detect EP receptors, cells were fixed and permeabilized before incubation with rabbit polyclonal anti-EP receptor Abs (EP1: 101740, EP2: 101750, EP3: 101760, EP4: 101775, Cayman Chemicals). Primary Abs were detected with Alexa Fluor 488-conjugated anti-rabbit IgG (A21206, Molecular Probe). PE-conjugated anti-F4/80 (clone BM8, e-bioscience) and APC-Cy7 conjugated anti-CD11b (clone M1-70, e-bioscience) were also labeled for macrophage gating. Labeled cells were analyzed on a LSRII flow cytometer (BD Biosciences).

Co-culture Experiments

BM-derived primary macrophages were seeded in 100 mm dishes (1×10^7 cells/10ml). After 3 days of differentiation, macrophages were transiently transfected with scrambled control siRNA or C/EBP β siRNA. After 24hr of transfection, transfected or non-transfected BM-derived macrophages were plated in 0.4 µm pore sized 24-transwell plates upper well at a density of 2×10^5 cells /well. For co-culture experiment, CD4+ T cells were isolated from splenocytes of Balb/c mice using a T cell enrichment kit (Miltenyi Biotec) and labeled with CFSE (Invitrogen). T cells (2×10^6 cells/well) were added into 24-well plate bottom wells in the presence of transfected macrophages or non-transfected macrophages. After indomethacin (20 µM or 100 µM) treatment to

the non-transfected group, T cells and macrophages were co-cultured for 4 days in the presence of anti-mouse CD3/CD28 antibodies (e-bioscience). T cell proliferation was examined using FACS analysis

Statistical analysis

Student's t-test or One-way ANOVA was used to determine statistical significance between groups using the GraphPad Prism Software (GraphPad, La Jolla, California, USA). P-value of less than 0.05 was considered to indicate statistical significance

RESULTS

Endogenous PGE₂ production is required for Arg1, IL10 and Mrc1 gene expression of macrophage.

In a preliminary study, we found that endogenous cyclooxygenase 1 and 2 are elevated throughout M-CSF grown macrophage differentiation. We therefore hypothesized that differentiating macrophages produce PGE₂ endogenously. To confirm macrophage mediated PGE₂ production during naïve differentiation, we serially collected culture supernatants after bone marrow cell seeding at differentiation days 1, 3, 5 and 7. As expected, macrophages produced PGE₂ continuously during differentiation (Fig. 1A). To test if PGE₂ production is mediated by endogenous cyclooxygenases, we treated the cells with indomethacin throughout the culture period. PGE₂ production rates increased following maturation and indomethacin significantly reduced PGE₂ synthesis in macrophages. We then examined C/EBP β as well as several anti-inflammatory C/EBP β target gene expressions after indomethacin treatment in macrophages to see the effects of reduced PGE₂ synthesis. Unless indicated, we used bone marrow cells at differentiation day 3 under M-CSF to reveal the effects of PGE₂ during macrophage differentiation more clearly. At this stage, F4/80 positive myeloid cell population is approximately half of that at more mature stage (Supplementary Figure S1). Surprisingly, cyclooxygenase inhibition by indomethacin rapidly decreased C/EBP β gene expression from 30 min, reaching 10% of control after 8 hr of indomethacin treatment (Fig. 1B). This suggests that endogenous C/EBP β production is mostly derived from the effect of microenvironmental PGE₂ on differentiating macrophages. C/EBP β target genes showed similar results. Arg1 gene expression decreased 12 hr after cyclooxygenase inhibition (Fig. 1C). IL10 and Mrc1 gene expression levels were almost abolished 8 hr after indomethacin treatment (Fig. 1D, E), indicating that these genes are directly induced by cyclooxygenase produced during macrophage differentiation. Taken together, cyclooxygenase mediates endogenous PGE₂ production, and therefore C/EBP β , Arg I, IL10 and Mrc1

gene expressions in macrophages.

PGE₂ phosphorylates CREB and increases C/EBP β .

To confirm the exact mechanism of PGE₂ mediated anti-inflammatory gene expressions, we examined time dependent CREB phosphorylation after PGE₂ treatment in macrophages. As expected, 10 μ M concentration of PGE₂ resulted in phosphorylated CREB starting at 10 min after treatment, which peaked at 30 min followed by a gradual decrease (Fig. 2A). To confirm the relationship of PGE₂ and C/EBP β in macrophages, we next examined whether PGE₂ could increase C/EBP β expression level by Western blotting. PGE₂ clearly increased C/EBP β protein expressions from 4 hr to 12 hr of treatment (Fig. 2B). This result matched with mRNA expression, which showed increased C/EBP β mRNA levels starting from 2 hr of PGE₂ treatment (Fig. 2C). J774A.1 cells showed similar results but C/EBP β mRNA synthesis was detected much earlier after PGE₂ treatment (Fig. 2D). These results show that PGE₂ increases C/EBP β through CREB phosphorylation in macrophages.

PGE₂ activates CREB through EP4 and EP2 receptors.

Before investigating the exact signaling pathway of PGE₂ in macrophages, we examined EP 1~4 receptor expressions in BMDMs from Balb/c mice. The two G_s-coupled receptors, EP2 and EP4, signal downstream to the adenylate cyclase-triggered cAMP/PKA/CREB pathway, which mediates the anti-inflammatory and suppressive activities of PGE₂ (17,18). In contrast, low-affinity EP1 and high-affinity EP3 are not coupled to G_s and lack cAMP-activating functions (19). Unexpectedly, FACS analysis showed that EP3 is the most abundant EP receptor, with EP4 second (Fig. 3A). EP1 and EP2 expressions were similar and detectable. Macrophages from C57BL/6 mice also showed the same results (Supplementary Figure S2). To examine which EP receptor is related with C/EBP β upregulation following PGE₂, EP agonists and antagonists were used (Fig. 3B). EP1/3 agonist Sulprostone did not phosphorylate CREB. On the other hand, EP2 agonist Butaprost and EP4 agonist CAY10598 strongly phosphorylated CREB in macrophages. EP2 and

EP4 agonists showed dose dependent CREB phosphorylation (unpublished observations) and the EP4 agonist was more potent. Accordingly, C/EBP β was upregulated only in EP2 and EP4 agonist treated macrophages and the EP4 agonist was also the most potent C/EBP β inducer. Next we pre-treated macrophages with EP antagonists 30 min before PGE₂ treatment and analyzed CREB phosphorylation levels. Paralleling agonist results, EP2 antagonist AH-6809 and EP4 antagonist AH-23848 inhibited PGE₂ mediated CREB phosphorylation as well as C/EBP β upregulation. EP1 antagonist SC-51089 and EP3 antagonist L-798,106 could not abrogate PGE₂ mediated CREB phosphorylation or C/EBP β upregulation. These results indicate that PGE₂ activates CREB and increases C/EBP β mainly through EP4 and, to a lesser degree, EP2 receptors, in macrophages.

PGE₂ activates CREB through the cAMP/PKA signaling pathway.

To confirm whether PGE₂ increases C/EBP β through the cAMP/PKA signaling pathway in macrophages, we treated adenylyl cyclase activator forskolin (10 μ M) and checked CREB phosphorylation and C/EBP β upregulation (Fig. 4A). PKA inhibitor H-89 abrogated both the PGE₂ and forskolin effects on CREB phosphorylation as well as C/EBP β upregulation. These results confirmed that PGE₂ uses the typical cAMP/PKA pathway to increase C/EBP β in macrophages. Next, we examined direct CREB involvement in transcriptionally upregulated C/EBP β (Fig. 4B, C). We overexpressed CREB, a dominant negative mutant KCREB that can be phosphorylated at serine 133 but cannot enter the nucleus, and the CREB133 vector which cannot be phosphorylated at serine 133 in RAW264.7 cells. After 24 hr post-transfection, PGE₂ was added and phospho-CREB was detected by Western blot. Wild-type CREB overexpressed cells showed increased total CREB proteins as well as phosphorylated CREB (Fig. 4B). However, increased CREB expression did not further upregulate C/EBP β induced by PGE₂ compared with empty vector control, possibly because endogenous CREB levels already saturate C/EBP β CRE binding sites. In contrast, KCREB and CREB133 vector increased total CREB, but KCREB

did not increase phosphorylation while CREB133 abolished phosphorylation. These mutant CREB overexpressions diminished C/EBP β upregulation by PGE₂. CHIP PCR of C/EBP β CRE after CREB pull down showed enhanced C/EBP β promoter binding of CREB with PGE₂ treatment but wildtype CREB overexpression could not further increase CRE binding as in Fig. 4B (Fig. 4C). However, mutant CREB overexpressed groups showed decreased CRE binding indicating that CREB directly induces C/EBP β transcription after PGE₂ treatment. Together, these results indicate that PGE₂ upregulates C/EBP β in macrophages through cAMP/PKA activation and CREB phosphorylation is followed by C/EBP β promoter CRE binding by activated CREB.

PGE₂ induces Arg1, IL10, MRC1 gene expression through C/EBP β .

Because C/EBP β is known to induce several M2 macrophage markers (20), we examined whether PGE₂ increased Arg1, IL10 and Mrc1 gene expressions via C/EBP β induction. Macrophages were transfected with scrambled control siRNA or C/EBP β siRNA for 24 hr. First, we confirmed that PGE₂ upregulates C/EBP β in scramble siRNA transfected macrophages but not in C/EBP β knockdown macrophages (Fig. 5A). C/EBP β siRNA efficiency was confirmed by Western blot (Fig. 5B). Next we investigated Arg1 (Fig. 5C), IL10 (Fig. 5D) and Mrc1 (Fig. 5E) gene expressions in both groups after PGE₂ treatment. Arginase 1 mRNA level was increased up to 13 times compared to control macrophages 8 hr after PGE₂ treatment, but was increased only 3 times in the C/EBP β knockdown macrophages (Fig. 5C). IL-10 mRNA level was increased by more than 60 times 12 hr after PGE₂ treatment in control cells and only 3 times in the C/EBP β knockdown macrophages (Fig. 5D). Macrophage mannose receptor Mrc1 gene expression was increased more than 110 times at 12 hr after PGE₂ in control macrophages, but increased only 10 times in the C/EBP β knockdown cells (Fig. 5E). These results support our hypothesis that PGE₂ potentiates anti-inflammatory phenotype of macrophage through C/EBP β upregulation and Arg1, IL10, Mrc1 gene expressions.

Cyclooxygenases and C/EBPβ in macrophages suppress T-cell proliferation.

Finally we investigated the functional implication of macrophage endogenous PGE₂ production on T cell proliferation. Macrophage Arginase 1 suppresses T cell proliferation by depleting local arginine which is needed for T cell proliferation (21). IL-10 can also suppress T cell activation (22). Because we observed PGE₂ mediated Arg1 and IL10 gene transcription, we next examined the functional implication of these effects on T cell suppression. Syngenic splenic CD4⁺ T cells were isolated and labeled with CFSE dye before co-culture with macrophages. Anti-CD3 and anti-CD28 antibodies were applied to T cells to measure proliferation. Macrophages were attached to the upper well of transwell plates and co-cultured with T cells for 4 days. Highly proliferating T cells (CFSE^{low} cells) were gated for our control experiment (Fig. 6A). We first attempted direct PGE₂ treatment of the co-culture environment, but this experimental group was omitted due to the massive inhibition of PGE₂ on T cell proliferation. When C/EBPβ knockdown macrophages were co-cultured with T cells, the CFSE^{low} T cell population increased in a dose dependent manner (Fig. 6B). In accordance with this, when indomethacin was applied for 4 days, the CFSE^{low} T cell population also increased dose dependently. Indomethacin treatment of T cells without macrophage co-culture did not affect CFSE^{low} percentages (data not shown). In summary, endogenous C/EBPβ and cyclooxygenase derived PGE₂ in macrophages have roles on inhibition of T cell proliferation.

Table 1. Primer sequences used in this study.

Target gene		sequence
CEBP β	Forward	5'-CGT TTC GGG ACT TGA TGC AAT C-3'
	Reverse	5'-CAA CAA CCC CGC AGG AAC AT-3'
IL-10	Forward	5'-CCA GGG AGA TCC TTT GAT GA-3'
	Reverse	5'-CAT TCC CAG AGG AAT TGC AT-3'
Mrc-1	Forward	5'-AAT GAA GAT CAC AAG CGC TGC-3'
	Reverse	5'-TGA CAC CCA GCG GAA TTT CT-3'
Arginase I	Forward	5'-GTC TGG CAG TTG GAA GCA TCT-3'
	Reverse	5'-GCA TCC ACC CAA ATG ACA CA-3'
	Probe (FAM)	5'-TGG CCA CGC CAG GGT CCA C-3'




FIGURE 1. Endogenous PGE₂ production is required for Arg1, IL10 and Mrcl macrophage gene expression. (A) PGE₂ production of bone marrow cell derived macrophages at the indicated differentiation day with M-CSF supplementation in the presence of indomethacin (100 μM) or not. Supernatants were harvested and PGE₂ levels were determined by EIA. (B-E) Macrophages at differentiation day 3 were treated with indomethacin (100 μM) for the indicated time points and RNAs were isolated. Relative mRNA levels of C/EBPβ (B), Arg1 (C), IL10 (D) and mrc1 (E) were measured by quantitative real-time PCR and normalized by GAPDH. Error bars, SD, *, p<0.05, **, p<0.005, ***, p<0.001 analyzed by one-way ANOVA with Bonferroni correction, n=3. Representative of three independent experiments.




FIGURE 2. PGE₂ phosphorylates CREB and increases C/EBPβ expression. (A and B) Bone marrow derived macrophages (BMDMs) were treated with 10 μM of PGE₂ and examined at the indicated time points. Phospho-CREB (p-CREB), C/EBPβ and actin expressions were detected by Western blotting. (C and D) Time course of C/EBPβ mRNA expression in BMDMs (C) and J774A.1 macrophage cell lines (D) after PGE₂ (10 μM) treatment. Data represents relative fold changes of PGE₂-treated cells compared with control, after normalization with endogenous GAPDH control. Error bars, SD, **, p<0.005, ***, p<0.001 analyzed by one-way ANOVA with Bonferroni correction, n=3. Representative of three independent experiments.




FIGURE 3. PGE₂ activates CREB through EP4 and EP2 receptors .

(A) EP receptor expression in BMDMs. Macrophages were fixed and stained with EP1~4 antibodies followed by rabbit Ax488 secondary antibody. Histograms were obtained by Flow cytometry. Mean fluorescence intensities of each EPs are indicated on right of histograms. (B) BMDMs were treated with PGE₂ (10 μM) for 30 min or the EP receptor agonists sulprostone (EP1/3 agonist, 10 μM), butaprost (EP2 agonist, 50 μM) and CAY10598 (EP4 agonist, 10 μM) for 1 hr. Cells were pre-treated with EP receptor antagonist SC-51089 (EP1 antagonist, 10 μM), AH-6809 (EP2 antagonist, 10 μM), L-798,106 (EP3 antagonist, 10μM) and AH-23848 (EP4 antagonist, 10 μM) for 30 min before PGE₂ (10μM) treatment, and then phospho-CREB and C/EBPβ were detected by Western Blot




FIGURE 4. PGE₂ activates CREB through the cAMP/PKA signaling pathway. (A) BMDMs were treated with PGE₂ (10 μM) or cAMP activator forskolin (10 μM) for 30min (CREB) or 2 hr (C/EBPβ) after pretreatment with PKA inhibitor H-89 (40 μM). Expression of phospho-CREB, CREB, C/EBPβ and actin were detected by Western blot. (B and C) Raw264.7 cells were transfected with wild-type CREB (CREB Vector), dominant-negative CREB (KCREB) or mutant CREB (CREB133) vectors. After 24 hr, cells were treated with PGE₂ (10 μM) for 30min (p-CREB) or 4 hr (C/EBPβ). (B) Expression of phospho-CREB and C/EBPβ were detected by Western Blot. (C) ChIP of CREB on the C/EBPβ promoter in Raw 264.7 macrophages. PCR specific for a 140-bp DNA fragment that spans the CRE elements in the C/EBPβ promoter was performed. Amplification of a 200-bp fragment in the 3'UTR was used as a control.




FIGURE 5. PGE₂ induces Arg1, IL10 and Mrcl macrophage gene expression through C/EBPβ. J774A.1 cells were transfected with scrambled control siRNA or C/EBPβ siRNA. After 24 hr, cells were treated with PGE₂ (10 μM) and RNAs were isolated at the indicated time points. Relative mRNA levels of C/EBPβ (A), Arginase I (C), IL-10 (D) and *mrc1* (E) were measured by quantitative real-time PCR. Macrophages were quantified using the relative CT method after endogenous GAPDH normalization. (B) C/EBPβ protein reduction by siRNA transduction was analyzed by Western blot. Error bars, SD, *, p<0.05, ***, p<0.001 analyzed by one-way ANOVA with Bonferroni correction, n=3. Representative of three independent experiments.




FIGURE 6. Endogenous cyclooxygenase and C/EBPβ in macrophages suppress T-cell proliferation. BMDMs were plated in the upper wells of 24-transwell plates at a density of 2×10^5 cells /well. CD4⁺ T cells were isolated from Balb/c splenocytes and labeled with CFSE before seeding in the bottom well at a density of 2×10^6 cells /well. T cells and macrophages were co-cultured for 4 days in the presence of anti-mouse CD3/CD28 antibodies. (A) T cell proliferation was analyzed by Flow cytometry. Only 7-AAD negative T cells were included and CFSE^{low} percentages were analyzed. (B) Macrophages were transfected with scrambled control siRNA or C/EBPβ siRNA for 24 hr before co-culture. (C) Macrophages were treated with indomethacin (20 μM or 100 μM) during the co-culture period. Error bars, SD, *, $p < 0.05$ analyzed by student t-test, $n=3$. Representative of three independent experiments.








FIGURE 7. Schematic representation of proposed mechanism by which endogenous PGE₂ promotes anti-inflammatory macrophage differentiation through the CREB/CEBPβ cascade. Schematic figure shows the effect of endogenous PGE₂ on macrophage differentiation. M-CSF derived cyclooxygenase induces PGE₂ production in macrophages. Other cell types may also produce PGE₂ in vivo. Signaling by EP2 and EP4 is triggered by PGE₂ binding, and then adenylylate cyclase is activated, leading to an increase in intracellular cAMP levels, which in turn activates PKA. Activated PKA then causes phosphorylation of CREB. This leads to transcription of C/EBPβ which promotes Arg1, IL10 and Mrc1 gene expression. Thus, endogenous PGE₂ promotes anti-inflammatory macrophage differentiation through the CREB/CEBPβ cascade.



Supplementary Figure 1. F4/80⁺ cell populations of differentiating bone marrow derived macrophages. Bone marrow cells from Balb/c mice were differentiated under M-CSF supplementation. At the indicated time points, attaching cells were scrapped and stained with F4/80 antibody followed by analysis using flow cytometry. (A) F4/80⁺ cell populations are shown in histograms. (B) Graph indicates each F4/80⁺ population percentages of differentiating macrophages



Supplementary Figure 2. EP receptor expression on bone marrow derived macrophages from C57BL/6J. Macrophages at differentiation day 3 were fixed and stained with EP1~4 antibodies followed by rabbit Ax488 secondary antibody. Histograms were obtained by Flow cytometry. Mean fluorescence intensities of each EPs are indicated on right of histograms.



Supplementary Figure 3. EP receptor expression on peritoneal macrophages of Balb/c and C57BL/6J mice. Peritoneal macrophages from Balb/c and C57BL/6J mice were fixed and stained with EP1-4 antibodies followed by rabbit Ax488 secondary antibody as well as F4/80 and CD11b antibodies. Macrophages were gated for F4/80 and CD11b double positive population and analyzed for EP receptor expression. Histograms were obtained by Flow cytometry. Numbers next to the histograms indicate mean fluorescence intensity

DISCUSSION

Macrophage phenotype is an emerging hot issue, because they serve central roles in the pathologies of various diseases including atherosclerosis, diabetes mellitus and cancer. For example, fat deposits progressively polarize macrophage into inflammatory phenotype by means of adipokines, leading to a systemic glucose insensitive state (23). Cancer cell derived M-CSF, CCL2 or PDGF-C lead to the generation and survival of immune-suppressive tumor associated macrophages, which function in angiogenesis and anti-tumor immunity (24, 25). Numerous efforts have been directed at finding key molecules governing macrophage polarization (Akt1/2, CARKLE, NF- κ B, IRF5, IRF4, etc) in order to manipulate macrophage phenotypes to overcome related diseases. Here, we demonstrate for the first time that endogenous PGE₂, an essential homeostatic factor, is a key mediator of immune suppressive macrophage phenotype and delineate the specific signals that regulate Arg1, IL10, Mrc1 gene expression. Specifically, M-CSF grown macrophages have an anti-inflammatory phenotype via the endogenously provided PGE₂/CREB-C/EBP β signaling cascade as illustrated in our schematic representation (Fig. 7).

C/EBP β expression is abundant in such macrophages as primary bone marrow derived macrophages, J774A.1, and RAW264.7 macrophage-like cell lines. The exact role of C/EBP β in macrophage differentiation has been examined in a few studies. While macrophage populations of C/EBP β knockout mice were normal in the blood, spleen, lymph nodes, skin and liver, the peritoneal and alveolar subpopulations were reduced, suggesting that the role of C/EBP β is tissue specific (26). Another study showed that C/EBP β deficiency does not affect the number nor the migration of macrophages in muscle (16). It did however affect the activity of macrophages in injury repair, demonstrating that C/EBP β is also involved in macrophage repair functions, not just macrophage survival or differentiation. Consistent with this, we also observed in this study that C/EBP β knockdown using siRNA in macrophages undergoing differentiation did not affect survival rates (data not shown).

C/EBP β was instead specifically involved in macrophage anti-inflammatory phenotype. It regulated Arg1, IL10 and Mrc1 gene expression (Fig. 5). Functionally, macrophage inhibition of T cell proliferation was impaired with lower expression of C/EBP β (Fig. 6). These results are supported by several reports that demonstrate that E3 ubiquitin ligase neuregulin receptor degradation protein 1 (Nrdp1) promotes M2 macrophage polarization by ubiquitinating C/EBP β (27). Arginase 1 induction, which thwarts effective immunity against intracellular pathogens (28), was well known target of C/EBP β (29). These studies and our current study collectively suggest that C/EBP β is critical in naïve homeostatic macrophage function.

Intriguingly, PGE₂ transcriptionally upregulates C/EBP β in macrophages (Fig. 2). To our knowledge, this is the first report demonstrating macrophage C/EBP β protein level regulation by PGE₂. More compellingly, macrophages produce PGE₂ during M-CSF induced differentiation. Endogenous PGE₂ clearly autologously affect C/EBP β gene expression, and subsequent Arg1, IL10 and Mrc1 gene expression in differentiating macrophages (Fig. 5). PGE₂ potentially originates from local stromal cells as well as epithelial cells, which are also possible candidates for affecting macrophage phenotype in vivo (11). Most studies regarding PGE₂ effects on macrophage have focused on mature macrophage functions. For example, PGE₂ is known to inhibit macrophage phagocytosis through EP2/cAMP (30), exert anti-inflammatory effects by reducing pro-inflammatory cytokines and enhances IL-10 (31-34), decreases bacterial killing through NADPH inhibition (35), and enhances cell membrane stability (36). Kerisztian Nemeth et al. underscored the effect of PGE₂ on immune inhibition in a systemic sepsis model when they proved that bone marrow stromal cells attenuate sepsis via PGE₂-dependent reprogramming of host macrophages to increase their IL-10 production (37). Only one study thus far has investigated the effect of PGE₂ on macrophage maturation (38). They found that EP2 was the most abundant PGE₂ receptor expressed by bone marrow derived macrophages and that PGE₂ restrains macrophage maturation via EP2/PKA signaling as determined by decreased F4/80 expression in EP2 deficient mice. In this context, our study conflicts with some of these results.

First of all, we found that the most abundant EP receptors on murine macrophages are EP3 and EP4 (Fig. 3, Supplementary Fig. S2), not EP2. Zbigniew Zaslona *et al.* examined EP expression in macrophages from C57BL/7 by mRNA levels, but our method using antibody labeling and FACS analysis is arguably more reliable in determining actual EP receptor surface expression. Furthermore, peritoneal macrophages from both Balb/c and C57BL/6 mice express more EP4 than EP2 (Supplementary Fig. S3). EP4 is also more potent for PGE₂ positive signaling than EP2, thus EP4 can partially counter EP2 deficiency. Another point is that F4/80 is not a reliable marker for macrophage maturation. GM-CSF grown mature macrophages express lower levels of F4/80 than M-CSF grown macrophages, indicating that its expression varies depending on macrophage phenotype. Our data supports that endogenous PGE₂ directs macrophage to the anti-inflammatory phenotype via EP2 and EP4 (primarily E4).

These findings mechanistically agree with the association of PGE₂ with the CREB-C/EBP β cascade given that EP2 and EP4 are coupled to a stimulatory G protein α subunit (*Gas*) (13). Ligand binding results in the exchange of GDP for GTP on the *Gas* protein and its subsequent dissociation from the $\beta\gamma$ subunit complex (39). The free *Gas* subunit stimulates the enzyme adenylyl cyclase (AC) to catalyze the cyclization of ATP to generate cAMP. cAMP dependent PKA activation phosphorylates CREB (40) and transcriptionally induces C/EBP β . Our results clearly show that AC activator forskolin phosphorylated CREB and enhanced C/EBP β . In addition, PKA inhibitor H89 inhibited CREB phosphorylation and decreased C/EBP β , and serine 133 mutant CREB could not bind C/EBP β CRE sufficiently (Fig. 4). Given that C/EBP β knockdown efficiency was incomplete (Fig. 5), it is understandable that Arg1 and IL10 were only partially inhibited following PGE₂ activation. Indomethacin on the other hand decreased Arg1, IL10, Mrc1 genes more than C/EBP β knockdown (Fig. 1). There are several possible reasons for these differences. PKA is known to activate p105 (34) and salt inducible kinase 2 (31). PGE₂ is thus likely able to alternatively induce IL10 gene expression aside from the CREB-C/EBP β cascade. CREB alone can also induce IL-10

without CEBP β activity (41), demonstrating the insufficiency of C/EBP β knockdown alone to completely inhibit Arg1, IL10, Mrc1 gene expressions. In a related study, we recently investigated long term COX inhibition mediated macrophage M1 polarization (under revision). This study adds another mechanistic level by showing that COX mediated PGE₂ production primarily differentiates macrophage to the anti-inflammatory phenotype. Besides macrophages, PGE₂ affects various other types of immune cells including NK cells (42, 43) and T cells (44). We also observed that long term COX-2 inhibitor treatment enhanced macrophage anti-tumor immunity and reduced regulatory T cell populations in breast tumor microenvironment (45). In concert with these studies, endogenous PGE₂ effects on differentiating macrophage shown in this study supports the general immune inhibitory function of PGE₂. This action is mainly mediated by the EP4/PKA/CREB-C/EBP β cascade. Together, our study has important implications for future efforts examining macrophage phenotypes in various PGE₂ altered pathological states.

REFERENCES

1. Wynn, T. A., Chawla, A., and Pollard, J. W. (2013) Macrophage biology in development, homeostasis and disease. *Nature* **496**, 445–455
2. Okabe, Y., and Medzhitov, R. (2014) Tissue-specific signals control reversible program of localization and functional polarization of macrophages. *Cell* **157**, 832–844
3. Gordon, S., and Taylor, P. R. (2005) Monocyte and macrophage heterogeneity. *Nature reviews. Immunology* **5**, 953–964
4. Yona, S., Kim, K. W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, S., Guillems, M., Misharin, A., Hume, D. A., Perlman, H., Malissen, B., Zelzer, E., and Jung, S. (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* **38**, 79–91
5. Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., Gordonov, S., Mazloom, A. R., Ma'ayan, A., Chua, W. J., Hansen, T. H., Turley, S. J., Merad, M., Randolph, G. J., and Immunological Genome, C. (2012) Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nature immunology* **13**, 1118–1128
6. Fleetwood, A. J., Lawrence, T., Hamilton, J. A., and Cook, A. D. (2007) Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. *Journal of immunology* **178**, 5245–5252
7. Gordon, S., and Martinez, F. O. (2010) Alternative activation of macrophages: mechanism and functions. *Immunity* **32**, 593–604
8. Stock, J. L., Shinjo, K., Burkhardt, J., Roach, M., Taniguchi, K., Ishikawa, T., Kim, H. S., Flannery, P. J., Coffman, T. M., McNeish, J. D., and Audoly, L. P. (2001) The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. *The Journal of clinical investigation* **107**, 325–331
9. Thorburn, G. D. (1992) The placenta, PGE2 and parturition. *Early human development* **29**, 63–73
10. Pecchi, E., Dallaporta, M., Jean, A., Thirion, S., and Troadec, J. D. (2009) Prostaglandins and sickness behavior: old story, new insights. *Physiology & behavior* **97**, 279–292
11. Kalinski, P. (2012) Regulation of immune responses by prostaglandin E2. *Journal of immunology* **188**, 21–28
12. Patel, S., and Chipilunkar, S. (2007) Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer. *Indian journal of biochemistry & biophysics* **44**, 419–428
13. Serezani, C. H., Ballinger, M. N., Aronoff, D. M., and Peters –

- Golden, M. (2008) Cyclic AMP: master regulator of innate immune cell function. *American journal of respiratory cell and molecular biology* **39**, 127-132
14. Martinez, F. O., Gordon, S., Locati, M., and Mantovani, A. (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *Journal of immunology* **177**, 7303-7311
 15. Mayr, B., and Montminy, M. (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. *Nature reviews. Molecular cell biology* **2**, 599-609
 16. Ruffell, D., Mourkioti, F., Gambardella, A., Kirstetter, P., Lopez, R. G., Rosenthal, N., and Nerlov, C. (2009) A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 17475-17480
 17. Fujino, H., Salvi, S., and Regan, J. W. (2005) Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. *Molecular pharmacology* **68**, 251-259
 18. Regan, J. W., Bailey, T. J., Pepperl, D. J., Pierce, K. L., Bogardus, A. M., Donello, J. E., Fairbairn, C. E., Kedzie, K. M., Woodward, D. F., and Gil, D. W. (1994) Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. *Molecular pharmacology* **46**, 213-220
 19. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A., and Narumiya, S. (1992) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. *The Journal of biological chemistry* **267**, 6463-6466
 20. Lawrence, T., and Natoli, G. (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. *Nature reviews. Immunology* **11**, 750-761
 21. Munder, M., Schneider, H., Luckner, C., Giese, T., Langhans, C. D., Fuentes, J. M., Kropf, P., Mueller, I., Kolb, A., Modolell, M., and Ho, A. D. (2006) Suppression of T-cell functions by human granulocyte arginase. *Blood* **108**, 1627-1634
 22. Saraiva, M., and O'Garra, A. (2010) The regulation of IL-10 production by immune cells. *Nature reviews. Immunology* **10**, 170-181
 23. Han, M. S., Jung, D. Y., Morel, C., Lakhani, S. A., Kim, J. K., Flavell, R. A., and Davis, R. J. (2013) JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. *Science* **339**, 218-222
 24. Ruffell, B., Affara, N. I., and Coussens, L. M. (2012) Differential

- macrophage programming in the tumor microenvironment. *Trends in immunology* **33**, 119–126
25. Son, D., Na, Y. R., Hwang, E. S., and Seok, S. H. (2014) Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation. *The Journal of biological chemistry* **289**, 6225–6235
 26. Cain, D. W., O'Koren, E. G., Kan, M. J., Womble, M., Sempowski, G. D., Hopper, K., Gunn, M. D., and Kelsoe, G. (2013) Identification of a tissue-specific, C/EBPbeta-dependent pathway of differentiation for murine peritoneal macrophages. *Journal of immunology* **191**, 4665–4675
 27. Ye, S., Xu, H., Jin, J., Yang, M., Wang, C., Yu, Y., and Cao, X. (2012) The E3 ubiquitin ligase neuregulin receptor degradation protein 1 (Nrdp1) promotes M2 macrophage polarization by ubiquitinating and activating transcription factor CCAAT/enhancer-binding Protein beta (C/EBPbeta). *The Journal of biological chemistry* **287**, 26740–26748
 28. El Kasmi, K. C., Qualls, J. E., Pesce, J. T., Smith, A. M., Thompson, R. W., Henao-Tamayo, M., Basaraba, R. J., Konig, T., Schleicher, U., Koo, M. S., Kaplan, G., Fitzgerald, K. A., Tuomanen, E. I., Orme, I. M., Kanneganti, T. D., Bogdan, C., Wynn, T. A., and Murray, P. J. (2008) Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. *Nature immunology* **9**, 1399–1406
 29. Albina, J. E., Mahoney, E. J., Daley, J. M., Wesche, D. E., Morris, S. M., Jr., and Reichner, J. S. (2005) Macrophage arginase regulation by CCAAT/enhancer-binding protein beta. *Shock* **23**, 168–172
 30. Aronoff, D. M., Canetti, C., and Peters-Golden, M. (2004) Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. *Journal of immunology* **173**, 559–565
 31. MacKenzie, K. F., Clark, K., Naqvi, S., McGuire, V. A., Noehren, G., Kristariyanto, Y., van den Bosch, M., Mudaliar, M., McCarthy, P. C., Pattison, M. J., Pedrioli, P. G., Barton, G. J., Toth, R., Prescott, A., and Arthur, J. S. (2013) PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. *Journal of immunology* **190**, 565–577
 32. Shi, J., Johansson, J., Woodling, N. S., Wang, Q., Montine, T. J., and Andreasson, K. (2010) The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. *Journal of immunology* **184**, 7207–7218
 33. van der Pouw Kraan, T. C., Boeije, L. C., Smeenk, R. J., Wijdenes, J., and Aarden, L. A. (1995) Prostaglandin-E2 is a

- potent inhibitor of human interleukin 12 production. *The Journal of experimental medicine* **181**, 775-779
34. Wall, E. A., Zavzavadjian, J. R., Chang, M. S., Randhawa, B., Zhu, X., Hsueh, R. C., Liu, J., Driver, A., Bao, X. R., Sternweis, P. C., Simon, M. I., and Fraser, I. D. (2009) Suppression of LPS-induced TNF- α production in macrophages by cAMP is mediated by PKA-AKAP95-p105. *Science signaling* **2**, ra28
 35. Serezani, C. H., Chung, J., Ballinger, M. N., Moore, B. B., Aronoff, D. M., and Peters-Golden, M. (2007) Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. *American journal of respiratory cell and molecular biology* **37**, 562-570
 36. Divangahi, M., Chen, M., Gan, H., Desjardins, D., Hickman, T. T., Lee, D. M., Fortune, S., Behar, S. M., and Remold, H. G. (2009) Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. *Nature immunology* **10**, 899-906
 37. Nemeth, K., Leelahavanichkul, A., Yuen, P. S., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., Hu, X., Jelinek, I., Star, R. A., and Mezey, E. (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nature medicine* **15**, 42-49
 38. Zaslona, Z., Serezani, C. H., Okunishi, K., Aronoff, D. M., and Peters-Golden, M. (2012) Prostaglandin E2 restrains macrophage maturation via E prostanoicd receptor 2/protein kinase A signaling. *Blood* **119**, 2358-2367
 39. Landry, Y., Niederhoffer, N., Sick, E., and Gies, J. P. (2006) Heptahelical and other G-protein-coupled receptors (GPCRs) signaling. *Current medicinal chemistry* **13**, 51-63
 40. Brindle, P., Linke, S., and Montminy, M. (1993) Protein-kinase-A-dependent activator in transcription factor CREB reveals new role for CREM repressors. *Nature* **364**, 821-824
 41. Mellett, M., Atzei, P., Jackson, R., O'Neill, L. A., and Moynagh, P. N. (2011) Mal mediates TLR-induced activation of CREB and expression of IL-10. *Journal of immunology* **186**, 4925-4935
 42. Joshi, P. C., Zhou, X., Cuchens, M., and Jones, Q. (2001) Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. *Journal of immunology* **166**, 885-891
 43. Walker, W., and Rotondo, D. (2004) Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. *Immunology* **111**, 298-305
 44. Walker, C., Kristensen, F., Bettens, F., and deWeck, A. L. (1983) Lymphokine regulation of activated (G1) lymphocytes. I

Prostaglandin E2-induced inhibition of interleukin 2 production.
Journal of immunology **130**, 1770-1773

45. Na, Y. R., Yoon, Y. N., Son, D. I., and Seok, S. H. (2013) Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. *PloS one* **8**, e63451

국문 초록

큰포식세포는 대부분의 장기에 상주하며 조직의 항상성 유지에 관여한다. 이러한 역할을 수행할 수 있는 것은 큰포식세포가 주위 환경에 민감하게 반응하여 자신의 특성을 변화시킬 수 있기 때문이며, 장기에 존재하는 큰포식세포가 각기 고유한 특징을 갖는 것 또한 장기마다의 미세 환경이 다르기 때문이다. 시기 적절한 큰포식세포의 활동이 제대로 이루어지지 못할 경우 만성 감염이나 조직의 손상 등의 병리학적 결과로 이어질 수 있어, 큰포식세포의 성격을 결정하는 인자의 규명을 위한 연구가 활발하게 진행되고 있다. 그러나 큰포식세포의 미세환경에 대한 영향과 단핵구로부터의 분화기전에 대한 이해는 의외로 부족한 실정이다. 따라서 본 연구에서, 연구자는 체내 항상성 유지에 관여하는 중요한 지질매개인자인 prostaglandin E₂(PGE₂)가 큰포식세포를 항염증의 성격을 갖도록 분화시킨다는 가정 하에 연구를 진행하였다. 그 결과, 단핵구 유래 큰포식세포가 PGE₂를 생산하고 분비하며, PGE₂가 M-CSF에 의해 큰포식세포로 분화하는 과정에 항염증성 큰포식세포의 마커 발현을 촉진시키는 것을 발견하였다. 또한 PGE₂는 Balb/c 마우스 골수 유래 큰포식세포에서 PGE₂수용체인 EP2 와 EP4를 활성화시켜 하위 신호전달과정에서 전사인자인 CREB의 인산화를 야기하였으며 이는 전사적으로 항염증성 큰포식세포와 관련한 전사인자인 C/EBP β 의 발현을 증가시켰다. 더 나아가 PGE₂가 이러한 CREB-C/EBP β cascade를 통해 arg1, IL10 그리고 Mrc1을 포함한 항염증성 큰포식세포 유전자 발현을 증가시킴을 확인하였다. 그리고 cyclic AMP를 활성화시키는 forskolin을 처리하였을 때 CREB가 인산화되어 C/EBP β cascade 가 유도되었으며 반대로 PKA 억제제인 H89를 처리하였을 때 완전하게 CREB 활성화가

저해되었다. 또한, NSAIDs의 일종인 indomethacin에 의해 COX activity를 저해하면 PGE₂ 분비량이 감소함과 동시에 항염증성 큰포식세포의 유전자 발현이 감소하는 것을 확인하였다. 종합해보면, 본 연구자는 이번 연구를 통해 큰포식세포가 M-CSF에 의한 분화 과정 중 PGE₂를 합성 분비하고, 여기서 분비된 PGE₂는 CREB-C/EBP β cascade 활성화로 이어지는 신호전달과정으로 항염증성 큰포식세포의 분화를 촉진할 수 있다는 것을 확인하였다.

주요어 : Prostaglandin E₂ (PGE₂), 항염증성 큰포식세포, CREB, C/EBP β

학 번 : 2013-21741